Discoid lupus erythematosus
ICD-10 L93.0 · ICD-11 EB51.0

Treatment of Discoid Lupus Erythematosus with Severe or Widespread Skin Lesions

This protocol covers the management of discoid lupus erythematosus (DLE) in patients with severe or widespread cutaneous involvement, or where there is a risk of scarring or progression to systemic disease, in patients who are not pregnant and not breastfeeding.

Clinical Scenario

Patients with active, severe, or widely distributed DLE lesions represent a population where escalated systemic treatment is indicated — particularly when permanent scarring or evolution toward systemic lupus is a concern.

Antimalarials are established as the cornerstone of long-term systemic treatment in all patients with severe or widespread cutaneous lupus lesions, with special priority for those at risk of scarring or systemic disease development.

Treatment Approach (partial overview)

The regimen for this patient group involves a retinoid-class agent or dapsone, used in combination with antimalarial therapy. The specific agent selection and the structure of the full regimen depend on individual clinical factors.

The complete protocol — including choice of agent, monitoring approach, and decision criteria — is available via the full regimen below.

Treatment Goal

The primary target is a measurable clinical response. When a retinoid agent is selected, response is expected to occur within 2 to 6 weeks of initiating treatment.

Instant Access to Structured Evidence-Based Regimens

References

  1. We recommend antimalarials as first-line and long-term systemic treatment in all CLE patients with severe or widespread skin lesions, in particular in patients with the risk of scarring and development of systemic disease.
  2. In severe or widespread active CLE lesions, systemic corticosteroids are recommended as first-line treatment in addition to antimalarials.
  3. We recommend retinoids as second-line systemic treatment in selected CLE patients unresponsive to other treatments, preferably in addition to antimalarials.
  4. In CLE, the recommended dose for acitretin and isotretinoin is 0.2 to 1.0 mg/kg body weight/day.
  5. We recommend dapsone as second-line treatment in refractory CLE, preferably in addition to antimalarials.
  6. We recommend to start dapsone with a low dose treatment (50 mg/day) and to increase it to a maximum of 1.5 mg/kg according to clinical response and side-effects.
  7. The response to retinoid therapy usually is rapid, occurring within the first 2 to 6 weeks of treatment.
View source ↗